Best GLP-1 Medications in Texas: 2026 Guide

Last updated: April 2026

Texas has become one of the largest markets for GLP-1 receptor agonist medications in the United States. With over 30 million residents and obesity rates hovering around 36.5% among adults (CDC Behavioral Risk Factor Surveillance System, 2024), the demand for effective weight-loss medications here is enormous. The state's sprawling geography — from the Rio Grande Valley to the Panhandle — makes access a real challenge for some patients, while others in metro areas like Houston, Dallas-Fort Worth, Austin, and San Antonio have dozens of options within a short drive.

This guide breaks down every GLP-1 medication available in Texas right now, what they cost, how to get them, and which one might be the best fit for your situation.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 receptor agonists are prescription medications with potential side effects and contraindications. Always consult a board-certified physician or endocrinologist before starting any GLP-1 medication. Individual results vary based on medical history, dosage, and lifestyle factors.

Affiliate Disclosure: The GLP-1 Daily may earn a commission from some links in this article. This does not affect our editorial recommendations or the price you pay.

---

What Are GLP-1 Medications and Why Are They So Popular in Texas?

GLP-1 receptor agonists mimic a hormone called glucagon-like peptide-1, which your gut naturally releases after eating. These medications slow gastric emptying, reduce appetite, and improve insulin sensitivity. The result: significant weight loss and better blood sugar control for most patients.

Texas sits at the intersection of several factors driving GLP-1 demand. The state has one of the highest adult obesity rates in the country, with 36.5% of adults classified as obese and another 33.1% overweight (CDC BRFSS, 2024). Type 2 diabetes affects roughly 13.3% of Texas adults, well above the national average of 11.6% (Texas DSHS, 2024). And the state's robust healthcare infrastructure — anchored by systems like UT Southwestern, Baylor Scott & White, Houston Methodist, and MD Anderson — means there are thousands of prescribing physicians.

How GLP-1s Work in Your Body

When you inject (or swallow, in the case of oral formulations) a GLP-1 medication, it binds to GLP-1 receptors in the brain, pancreas, and gut. In the hypothalamus, it reduces hunger signals. In the pancreas, it stimulates insulin release while suppressing glucagon. In the stomach, it slows the rate at which food moves through your digestive system.

The net effect is that you feel full faster, stay full longer, and your blood sugar stays more stable. Clinical trials have shown weight loss ranging from 15% to 22.5% of body weight depending on the specific medication and dosage (SURMOUNT-1, 2022; STEP 1, 2021).

Why Texas Specifically?

Beyond the high obesity and diabetes rates, Texas has a few structural features that make it a particularly active GLP-1 market:

• Large employer base: Texas has more Fortune 500 headquarters than any other state. These large employers are increasingly adding GLP-1 coverage to their health plans.
• Telehealth-friendly laws: Texas expanded telehealth regulations in 2021, and the state allows GLP-1 prescriptions via telemedicine after an initial virtual consultation.
• Compounding pharmacy access: Texas has a high concentration of 503A and 503B compounding pharmacies, giving patients access to compounded semaglutide and tirzepatide at lower prices.
• No state income tax: Texans generally have higher take-home pay, which may make out-of-pocket medication costs more manageable for some patients.

Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital and associate professor at Harvard Medical School, has noted: "The states with the highest obesity rates are often the ones where we see the most aggressive adoption of GLP-1 therapies. Texas is a prime example — the demand is there, and the healthcare infrastructure is growing to meet it."

---

Which GLP-1 Medications Are Available in Texas Right Now?

As of April 2026, Texas patients have access to every FDA-approved GLP-1 and dual-agonist medication on the market. Here's the full breakdown.

Semaglutide Injections (Wegovy and Ozempic)

Semaglutide is the active ingredient in both Wegovy (approved for weight management) and Ozempic (approved for type 2 diabetes). They're the same molecule at different doses.

Wegovy is dosed at up to 2.4 mg weekly for weight loss. In the STEP 1 trial, participants lost an average of 14.9% of their body weight over 68 weeks (Wilding et al., New England Journal of Medicine, 2021). The SELECT trial later confirmed cardiovascular benefits, showing a 20% reduction in major adverse cardiovascular events among people with overweight/obesity and established cardiovascular disease (Lincoff et al., NEJM, 2023).

Ozempic tops out at 2.0 mg weekly and is technically indicated for type 2 diabetes, though many physicians prescribe it off-label for weight loss when Wegovy is unavailable or too expensive.

Texas pricing (April 2026):

• Wegovy without insurance: ~$1,349/month (list price)
• Ozempic without insurance: ~$935/month (list price)
• With commercial insurance copay cards: as low as $0–$25/month for qualifying patients
• GoodRx cash price for Ozempic in Houston: ~$780–$890/month
• GoodRx cash price for Wegovy in Dallas: ~$1,100–$1,300/month

Key stat: Novo Nordisk reported that U.S. Wegovy prescriptions grew 40% year-over-year in 2025, with Texas ranking as the third-largest state market by total prescriptions (Novo Nordisk Annual Report, 2025).

Tirzepatide Injections (Zepbound and Mounjaro)

Tirzepatide is a dual GIP/GLP-1 receptor agonist — it hits two targets instead of one. This dual action appears to produce greater weight loss and glucose control compared to GLP-1-only drugs.

Zepbound is the weight-management version, approved in November 2023. In the SURMOUNT-1 trial, the highest dose (15 mg) produced average weight loss of 22.5% over 72 weeks — the most of any approved anti-obesity medication (Jastreboff et al., NEJM, 2022).

Mounjaro is the type 2 diabetes version. In the SURPASS trials, tirzepatide reduced A1C by up to 2.3% and produced weight loss of up to 25 pounds at the highest dose (Frías et al., NEJM, 2021).

Texas pricing (April 2026):

• Zepbound without insurance: ~$1,059/month (list price)
• Mounjaro without insurance: ~$1,023/month (list price)
• Eli Lilly savings card: as low as $25/month for commercially insured patients
• Zepbound vial program (self-pay): ~$399–$549/month for the lower doses
• GoodRx cash price for Mounjaro in San Antonio: ~$900–$1,010/month

Eli Lilly's direct vial program has been a game-changer for Texas patients without insurance coverage. The vials require drawing the medication yourself, but the cost savings are substantial.

Oral Semaglutide (Rybelsus and New Oral Formulations)

Rybelsus is the only oral GLP-1 currently on the market, approved for type 2 diabetes at doses up to 14 mg daily. It's not approved for weight loss, and the weight-loss results at the current dose are modest compared to injectable semaglutide — about 4–5% body weight reduction. For a deeper look at how the new oral formulations stack up, read our coverage of the FDA's approval of the latest oral GLP-1 medications.

However, higher-dose oral semaglutide (25 mg and 50 mg) is in late-stage trials, and Novo Nordisk has indicated these could match injectable results. The OASIS 1 trial showed 15.1% weight loss with the 50 mg oral dose at 68 weeks (Knop et al., The Lancet, 2023).

Texas pricing (April 2026):

• Rybelsus 14 mg without insurance: ~$936/month
• With manufacturer copay card: as low as $10/month for eligible patients

Liraglutide (Saxenda and Victoza)

Liraglutide was the first GLP-1 approved for weight management (as Saxenda, in 2014). It requires daily injections and produces less weight loss than semaglutide or tirzepatide — about 8% of body weight on average in the SCALE trial (Pi-Sunyer et al., NEJM, 2015).

It's still available in Texas and sometimes prescribed when patients can't tolerate semaglutide or tirzepatide, or when insurance covers Saxenda but not the newer options. Saxenda is also one of the few GLP-1s approved for adolescents aged 12 and older.

Texas pricing (April 2026):

• Saxenda without insurance: ~$1,349/month
• Generic liraglutide: Not yet available (patent expiration pending)

What's Coming Next: Pipeline Drugs

Several next-generation GLP-1 and multi-agonist medications are in late-stage development and could reach Texas patients within 12–24 months:

• Retatrutide (Eli Lilly): A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 results showed up to 24.2% weight loss at 48 weeks (Jastreboff et al., NEJM, 2023). Phase 3 trials are ongoing.
• CagriSema (Novo Nordisk): Combines semaglutide with cagrilintide (an amylin analog). Phase 3 results are expected in 2026.
• Orforglipron (Eli Lilly): An oral non-peptide GLP-1 that doesn't require fasting before taking it, unlike Rybelsus. Phase 3 trials are ongoing.
• Survodutide (Boehringer Ingelheim/Zealand Pharma): A GLP-1/glucagon dual agonist showing strong results for MASH (metabolic dysfunction-associated steatohepatitis) and obesity.

---

How Much Do GLP-1 Medications Cost in Texas Without Insurance?

Cost is the single biggest barrier to GLP-1 access in Texas. Let's get specific about what you'll actually pay.

Brand-Name List Prices (April 2026)

Medication	Monthly List Price	Best Cash Price (GoodRx TX avg)
Wegovy (semaglutide 2.4 mg)	$1,349	$1,100–$1,300
Ozempic (semaglutide 1.0–2.0 mg)	$935	$780–$890
Zepbound (tirzepatide, varies)	$1,059	$900–$1,050
Mounjaro (tirzepatide, varies)	$1,023	$900–$1,010
Rybelsus (oral semaglutide 14 mg)	$936	$800–$900
Saxenda (liraglutide 3.0 mg)	$1,349	$1,100–$1,250

Compounded Alternatives in Texas

Compounded semaglutide and tirzepatide are available from licensed compounding pharmacies in Texas. These are custom-mixed versions of the same active ingredients, typically offered at a fraction of the brand-name price.

Important context: The FDA's stance on compounded GLP-1s has shifted repeatedly. As of early 2026, compounded semaglutide remains available under the FDA's shortage provisions, though this could change. Compounded tirzepatide faces tighter restrictions after Eli Lilly challenged its availability in court. Always verify with your provider that your compounded medication comes from a 503A or 503B-accredited pharmacy.

Typical compounded pricing in Texas:

• Compounded semaglutide: $169–$299/month
• Compounded tirzepatide: $299–$499/month

Texas-based compounding pharmacies include Empower Pharmacy (Houston), which operates as a 503B outsourcing facility and has been one of the largest compounders of semaglutide in the country.

Manufacturer Savings Programs

Both Novo Nordisk and Eli Lilly offer savings programs that can dramatically reduce out-of-pocket costs for patients with commercial insurance:

• Wegovy Savings Card: Eligible patients with commercial insurance pay as low as $0/month for up to 28 days of supply. Maximum savings of $500/fill.
• Ozempic Savings Card: As low as $25/month for up to 24 months for eligible patients with commercial insurance.
• Zepbound/Mounjaro Savings Card: As low as $25/month for eligible patients. Eli Lilly has been notably aggressive with this program.
• Novo Nordisk Patient Assistance Program (PAP): Free medication for uninsured patients meeting income requirements (generally household income below 400% of the federal poverty level).
• Eli Lilly Solutions Center: Similar patient assistance for uninsured patients.

---

Does Insurance Cover GLP-1 Medications in Texas?

Insurance coverage for GLP-1s in Texas is a patchwork. Some patients get full coverage with a small copay. Others face prior authorization battles, step therapy requirements, or outright denials. Here's how it breaks down by insurance type.

Employer-Sponsored Insurance

Large employers in Texas are increasingly covering GLP-1 medications for weight management, driven by evidence that the drugs reduce healthcare costs over time. A KFF survey found that 19% of large firms (200+ employees) covered GLP-1s for weight loss in 2024 — but in Texas specifically, that number is higher due to the concentration of large employers in energy, technology, and healthcare sectors.

However, coverage doesn't mean hassle-free access. Most plans require:

• Prior authorization: Your doctor must document that you meet BMI criteria (generally 30+ or 27+ with a weight-related comorbidity)
• Step therapy: Some plans require you to try and fail cheaper options (like naltrexone/bupropion or phentermine) before approving a GLP-1
• Specialist referral: Some plans want you to see an endocrinologist or obesity medicine specialist rather than a primary care physician

For a complete state-by-state breakdown including Texas employer plans, check our GLP-1 insurance coverage guide for 2026.

Texas Medicaid

Texas Medicaid covers GLP-1 medications for type 2 diabetes but does not cover them for weight management alone as of April 2026. This is consistent with most state Medicaid programs, though a few states (New York, California) have begun piloting weight-management coverage.

For Medicaid patients with both diabetes and obesity, prior authorization is required. The Texas Health and Human Services Commission (HHSC) maintains a preferred drug list that includes semaglutide and tirzepatide for diabetes indications.

Medicare Part D in Texas

Medicare Part D began covering Wegovy for cardiovascular risk reduction in January 2026, following the SELECT trial results. This is a significant change — previously, Medicare explicitly excluded anti-obesity medications.

However, the coverage is narrow:

• You must have established cardiovascular disease (not just risk factors)
• The prescription must be written specifically for cardiovascular risk reduction
• Prior authorization is required
• Not all Part D plans have added Wegovy to their formularies yet

Medicare does not cover GLP-1s purely for weight loss. For diabetes, Ozempic, Mounjaro, and Rybelsus are covered under most Part D plans with varying copay tiers.

Texas Blue Cross Blue Shield, Aetna, UnitedHealthcare, and Cigna

The four largest commercial insurers in Texas each handle GLP-1 coverage differently:

• BCBS of Texas: Covers Wegovy and Zepbound for weight management on most employer plans, with prior authorization. Ozempic and Mounjaro covered for diabetes. Formulary position varies by plan.
• UnitedHealthcare: Has been one of the more restrictive insurers for weight-management GLP-1s. Coverage depends heavily on the specific employer plan. Many UHC plans require step therapy.
• Aetna: Added Zepbound to its preferred formulary for weight management in mid-2025. Prior authorization required. Wegovy covered on most plans.
• Cigna/Evernorth: Coverage varies by plan. Cigna's specialty pharmacy division, Accredo, handles GLP-1 fulfillment for many plans, which can create additional delays.

Pro tip: If your insurance denies a GLP-1 for weight management, ask your doctor to submit a peer-to-peer review. In Texas, insurers must respond to peer-to-peer requests within a specific timeframe. Many denials are overturned at this stage.

---

Where Can You Get GLP-1 Medications in Texas? Best Clinics, Pharmacies, and Telehealth Options

Texas patients have three main channels for accessing GLP-1 medications: in-person clinics, retail/specialty pharmacies, and telehealth platforms. Each has tradeoffs.

In-Person Obesity Medicine Clinics

Texas has a strong network of board-certified obesity medicine physicians, particularly in the major metro areas. These clinics offer comprehensive programs that typically include:

• Initial consultation with body composition analysis (DEXA or bioimpedance)
• Lab work (metabolic panel, A1C, thyroid, lipids)
• GLP-1 prescription with ongoing dose titration
• Nutritional counseling and exercise guidance
• Monthly or quarterly follow-up visits

Top Texas metro areas for in-person GLP-1 clinics:

• Houston: The largest medical center in the world (Texas Medical Center) offers dozens of obesity medicine practices. UT Physicians, Houston Methodist, and Memorial Hermann all have dedicated weight management programs.
• Dallas-Fort Worth: UT Southwestern's weight management program is among the most respected in the state. Baylor Scott & White also operates multiple locations with obesity medicine specialists.
• San Antonio: UT Health San Antonio and the Bariatric Medical Institute of Texas are key providers.
• Austin: Texas Obesity Specialists and Austin Regional Clinic both prescribe GLP-1 medications as part of structured programs.

In-person clinics typically charge $200–$500 for an initial consultation, plus $100–$250 for follow-up visits. Some accept insurance; many are cash-pay.

Retail and Specialty Pharmacies

Once you have a prescription, you can fill it at most major pharmacies in Texas:

• CVS: Carries all brand-name GLP-1s. CVS Specialty handles tier-3 GLP-1 prescriptions for some insurance plans.
• Walgreens: Full GLP-1 availability. Walgreens also offers its own weight-management telehealth program in partnership with medical providers.
• H-E-B Pharmacy: Texas's beloved grocery chain fills GLP-1 prescriptions and often has competitive cash pricing.
• Costco Pharmacy: Consistently among the lowest cash prices for GLP-1s in Texas. You don't need a Costco membership to use the pharmacy.
• Amazon Pharmacy: Delivers GLP-1 medications to Texas addresses, sometimes at lower prices than brick-and-mortar.

Telehealth Platforms Serving Texas

Telehealth has become the most popular way to start GLP-1 treatment in Texas, especially for patients who don't have easy access to an obesity medicine specialist or who want a faster, more affordable path to treatment.

Major telehealth providers available in Texas:

Platform	Monthly Cost (medication included)	What You Get
Ro	$199+/month (compounded semaglutide)	Virtual consultation, medication delivered, ongoing provider access
Hims/Hers	$199+/month (compounded semaglutide)	Virtual visit, medication delivered, messaging with provider
Found	$129+/month (consultation only)	Virtual visit, Rx sent to pharmacy, behavior coaching
PlushCare	$99/visit (Rx only)	Virtual visit, Rx sent to your pharmacy, accepts some insurance
Calibrate	$199/month (program fee)	Year-long program, metabolic labs, coaching, Rx management
WeightWatchers Clinic	$99/month (medication extra)	Virtual visits, GLP-1 Rx, WW coaching integration

Dr. Jaime Almandoz, medical director of the Weight Wellness Program at UT Southwestern in Dallas, has observed: "Telehealth has been transformative for GLP-1 access in Texas, particularly in rural areas. We see patients from West Texas and the Panhandle who previously had to drive three or four hours to see a weight management specialist. Now they can get a prescription and have medication delivered to their door."

What to watch out for with telehealth:

• Make sure the provider is licensed in Texas (not just their home state)
• Verify that the compounding pharmacy they use is 503A or 503B accredited
• Check whether the monthly fee includes medication or just the consultation
• Ask about dose titration protocols — good providers will start you low and increase gradually
• Confirm you'll have access to a real physician or NP, not just automated refills

---

How Do You Choose the Right GLP-1 Medication for You?

With multiple GLP-1 options on the market, the "best" medication depends on your specific health profile, goals, insurance coverage, and tolerance for side effects. Here's a framework for thinking through the decision.

Semaglutide vs. Tirzepatide: Head-to-Head

The most common question Texas patients ask is whether they should take semaglutide or tirzepatide. While there's no single right answer, the clinical data points in a clear direction.

Weight loss: Tirzepatide produces more weight loss on average. The SURMOUNT-1 trial showed 22.5% body weight reduction with tirzepatide 15 mg, compared to 14.9% with semaglutide 2.4 mg in STEP 1. However, these are different trials with different patient populations — the head-to-head SURMOUNT-5 trial (tirzepatide vs. semaglutide directly) showed tirzepatide achieving 20.2% vs. semaglutide's 13.7% weight loss at 72 weeks (Frías et al., Nature Medicine, 2025).

Blood sugar control: Both are excellent for type 2 diabetes. Tirzepatide reduced A1C by up to 2.3% in SURPASS-2, compared to semaglutide's 1.8% in SUSTAIN-7. Again, different trials, but the dual mechanism appears to offer an edge. For a deeper dive into the diabetes-specific data, read our Tirzepatide vs Semaglutide for Diabetes Control: 2026 Head-to-Head.

Side effects: Both share the same core side effects — nausea, vomiting, diarrhea, and constipation. These are most common during dose escalation and typically improve over time. In clinical trials, the side effect profiles were broadly similar, though some patients tolerate one better than the other. For practical strategies on managing side effects, our guide to the best protein powders for GLP-1 users includes nutrition tips that help reduce nausea.

Cost: List prices are similar, but Eli Lilly's Zepbound vial program offers a lower-cost option for self-pay patients that Novo Nordisk doesn't currently match for Wegovy.

Insurance: Coverage varies. In some Texas plans, semaglutide is preferred; in others, tirzepatide is. This often ends up being the deciding factor.

Injectable vs. Oral: Which Route Is Right for You?

Currently, the only oral option is Rybelsus, and it produces significantly less weight loss than injectable GLP-1s at approved doses. However, the pipeline of oral options is expanding rapidly.

Choose injectable if:

• Weight loss is your primary goal
• You don't mind weekly injections (the needles are small — most patients say it's no worse than a fingerstick)
• You want the strongest clinical evidence behind your treatment

Consider oral if:

• You have a genuine needle phobia that can't be managed
• You need a GLP-1 primarily for blood sugar control (not weight loss)
• You're willing to wait for higher-dose oral formulations currently in trials

When Liraglutide (Saxenda) Still Makes Sense

Saxenda isn't the most effective GLP-1 for weight loss, but it has specific use cases:

• Adolescents: Saxenda is approved for ages 12+, while Wegovy and Zepbound have more limited pediatric data
• Insurance coverage: Some legacy insurance plans cover Saxenda but haven't added newer GLP-1s
• Shorter commitment: The daily injection schedule means the drug clears your system faster if you stop, which some patients prefer
• Prior authorization strategy: Some insurers require patients to try Saxenda before approving semaglutide or tirzepatide

---

What Are the Side Effects of GLP-1 Medications and How Do Texas Doctors Manage Them?

Side effects are the number-one reason patients discontinue GLP-1 medications. Understanding what to expect — and how to manage it — is critical to success.

Common Side Effects (Experienced by 20–50% of Patients)

Nausea: The most reported side effect, affecting 40–50% of patients during dose titration. It typically peaks in the first 2–4 weeks at each new dose level and subsides. Texas providers commonly recommend:

• Eating smaller, more frequent meals (5–6 per day instead of 3)
• Avoiding high-fat and greasy foods
• Taking the injection in the evening so the worst nausea occurs during sleep
• Using ginger tea or supplements for mild nausea
• Prescription ondansetron (Zofran) for severe cases

Constipation and diarrhea: GLP-1s slow gut motility, which can swing between constipation and diarrhea. Fiber supplementation, adequate water intake (minimum 64 oz/day), and a daily probiotic are standard recommendations from Texas obesity medicine practitioners.

Injection site reactions: Mild redness, itching, or bruising at the injection site. Rotating injection sites (abdomen, thigh, upper arm) minimizes this.

Fatigue: Many patients report fatigue in the first few weeks, often related to reduced caloric intake rather than the medication itself. Ensuring adequate protein intake (0.7–1.0 g per pound of body weight per day) and not dropping calories too dramatically can help.

Less Common but Serious Side Effects

Pancreatitis: Rare but serious. If you experience severe, persistent abdominal pain radiating to the back, stop the medication and contact your doctor or go to the ER immediately. Clinical trials show pancreatitis rates of <1% across all GLP-1s.

Gallbladder issues: Rapid weight loss from any cause increases gallbladder disease risk. GLP-1 users should be aware of symptoms: sharp pain in the upper right abdomen, especially after eating fatty foods.

Thyroid concerns: GLP-1 medications carry a boxed warning about medullary thyroid carcinoma (MTC) based on animal studies. The risk in humans is not established but is being monitored. Patients with a personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN2) should not use these medications.

Gastroparesis concerns: The FDA has received reports linking GLP-1 use to gastroparesis (delayed stomach emptying) that persists after stopping the medication. This is being actively studied, but the overall incidence appears low. Research into the broader neurological effects of GLP-1 medications continues to yield surprising findings — our article on GLP-1 medications and addiction and brain health research covers some of this emerging science.

Muscle Loss: The Hidden Risk

One of the most discussed concerns with GLP-1 medications is muscle loss during weight loss. In the STEP 1 trial, about 40% of the total weight lost with semaglutide was lean body mass (including muscle). This is consistent with weight loss from any method — roughly one-third to one-half of weight loss is typically lean mass.

Texas-based providers increasingly emphasize concurrent strength training and high-protein diets to minimize muscle loss. The American College of Sports Medicine recommends at least two days per week of resistance training for GLP-1 users, targeting all major muscle groups.

---

Texas-Specific Access Issues: Rural Areas, Border Communities, and the Uninsured

Texas presents unique access challenges that patients in smaller or more urban states don't face.

Rural Texas

About 15% of Texans live in rural areas, many of which are designated Health Professional Shortage Areas (HPSAs). In these communities:

• The nearest endocrinologist or obesity medicine specialist may be 100+ miles away
• Local pharmacies may not stock GLP-1 medications due to low demand and high inventory costs
• Internet connectivity for telehealth can be unreliable in some regions

Solutions: Telehealth platforms that ship medication directly are the primary workaround. Several Texas health systems, including Texas Tech University Health Sciences Center in Lubbock, have expanded their virtual weight management programs specifically to serve rural patients. Mail-order pharmacy services from CVS Caremark, Express Scripts, and Amazon Pharmacy can deliver to any Texas address.

Border Communities

Texas's border region with Mexico presents a unique dynamic. Some patients cross into Mexico to purchase GLP-1 medications at Mexican pharmacies, where semaglutide and liraglutide are available at significantly lower prices (often 60–70% less than U.S. list prices).

Important warning: While purchasing medications in Mexico for personal use is technically tolerated at the border (though not formally legal in most cases), there are real risks:

• Counterfeit medications are common. The WHO estimates that up to 10% of medications in developing countries are counterfeit or substandard (WHO, 2023).
• Proper cold chain storage may not be maintained
• You won't have a U.S. physician monitoring your treatment
• Customs may confiscate injectable medications

The safest approach is to work with a licensed U.S. provider and explore manufacturer assistance programs, compounded alternatives, or telehealth options if brand-name pricing is a barrier.

The Uninsured in Texas

Texas has the highest uninsured rate in the nation — roughly 16.6% of adults lack health insurance (Census Bureau, 2024). For these patients, GLP-1 access is particularly challenging since brand-name medications cost $900+ per month.

Options for uninsured Texans:

• Manufacturer patient assistance programs: Both Novo Nordisk and Eli Lilly offer free or low-cost medications for qualifying patients (income-based)
• Compounded medications: $169–$399/month through licensed compounding pharmacies
• Community health centers: Federally Qualified Health Centers (FQHCs) in Texas may be able to prescribe GLP-1s and connect patients with assistance programs. Texas has over 75 FQHC organizations with 600+ delivery sites.
• Eli Lilly Zepbound vial program: Available to self-pay patients at reduced prices
• Clinical trials: Texas is a major hub for GLP-1 clinical research, with active trials at UT Southwestern, Baylor, Houston Methodist, and other institutions. ClinicalTrials.gov lists current enrollment opportunities.

---

What Should You Ask Your Doctor Before Starting a GLP-1 in Texas?

Walking into a doctor's appointment prepared makes the process faster and increases your chances of getting the right medication on the first try. Here are the specific questions to ask.

Before the Appointment

Gather this information before your visit:

• Your current weight, height, and BMI (BMI calculator available on the CDC website)
• A list of all current medications and supplements
• Your insurance card and a copy of the formulary (or call your insurer to ask which GLP-1s are covered)
• Any prior attempts at weight management (diets, programs, medications, surgery consultations)
• Family history of thyroid cancer, pancreatitis, or MEN2 syndrome

Key Questions for Your Provider

1. "Based on my health profile, do you recommend semaglutide or tirzepatide?" — Let your doctor weigh the clinical factors rather than choosing based on marketing.

2. "What's the prior authorization process with my insurance, and how long does it typically take?" — In Texas, prior auth for GLP-1s typically takes 3–10 business days. Some offices have staff dedicated to this process.

3. "What's your dose titration schedule?" — Good providers start at the lowest dose and increase every 4 weeks, not faster. Rushing titration increases side effects and dropout rates.

4. "What's your protocol for monitoring during treatment?" — Look for providers who check metabolic labs, monitor weight and body composition, and schedule regular follow-ups (monthly for the first 3 months, then quarterly).

5. "Do you recommend any concurrent interventions?" — The best outcomes come from combining GLP-1 medications with structured nutrition (high protein, adequate fiber), resistance training, and behavioral support.

6. "What's your plan if this medication doesn't work or I can't tolerate it?" — Having a backup plan (switching medications, adjusting doses, adding other interventions) from the start reduces frustration.

7. "How long do you typically keep patients on GLP-1 medications?" — Most obesity medicine physicians now view GLP-1s as long-term or indefinite treatment. The STEP 4 trial showed that patients who stopped semaglutide regained about two-thirds of the weight they'd lost within a year (Rubino et al., JAMA, 2024). Discuss expectations upfront.

---

How We Ranked

GLP-1 rankings (medications, providers, comparisons) combine:

1. Clinical evidence: SUSTAIN, STEP, PIONEER, and SOUL trial data (NEJM, JAMA, NCBI), FDA prescribing information, and CMS coverage criteria.
2. Patient-reported outcomes: r/Semaglutide, r/Tirzepatide, r/GLP1, and the verified GLP-1 Daily community from the past 12 months. We track patterns in supply shortages, compounding-pharmacy reports, and adverse-event clustering.
3. First-hand provider testing: editorial telehealth consults to each ranked provider verifying drug source, lab requirements, and continuity of care.

What we never accept: paid placement, compounding-pharmacy referral fees, or sponsorships that influence brand recommendations. Disclosure: affiliate links to vitamin and HSA-related resources appear elsewhere on the site and never affect medication or provider rankings.

Update cadence: each provider quarterly; pricing on demand. Last-updated at top. Email research@theglp1daily.com.

Frequently Asked Questions

Can I get GLP-1 medications delivered to my home in Texas?

Yes. Multiple telehealth platforms (Ro, Hims, Found, PlushCare) deliver GLP-1 medications directly to Texas addresses, typically via cold-chain shipping with ice packs. Retail mail-order pharmacies like CVS Caremark, Express Scripts, and Amazon Pharmacy also deliver to Texas. Compounded medications from 503B pharmacies like Empower Pharmacy in Houston ship nationwide. Delivery typically takes 3–7 business days, and most providers offer expedited shipping for an additional fee.

Is compounded semaglutide legal and safe in Texas?

As of April 2026, compounded semaglutide is legal in Texas under the FDA's shortage provisions. Compounding pharmacies that operate under 503A (state-licensed) or 503B (FDA-registered) designations can legally produce compounded semaglutide. Safety depends on the pharmacy — look for accreditation from the Pharmacy Compounding Accreditation Board (PCAB) or a current FDA registration for 503B facilities. Always request a Certificate of Analysis showing the medication's potency and sterility testing. The legal landscape could shift if the FDA removes semaglutide from the shortage list, so stay informed through your provider.

What BMI do I need to qualify for a GLP-1 prescription in Texas?

The standard medical criteria are: BMI of 30 or higher (obesity), or BMI of 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea. For diabetes-specific GLP-1 prescriptions (Ozempic, Mounjaro, Rybelsus), a type 2 diabetes diagnosis is the primary criterion regardless of BMI. Some telehealth platforms have slightly different internal guidelines, but these are the FDA-approved indications that insurance companies use for coverage decisions. Texas physicians may also prescribe off-label in clinical scenarios where they judge the benefit outweighs the risk.

Does Texas Medicaid cover GLP-1 medications?

Texas Medicaid covers GLP-1 medications for type 2 diabetes (Ozempic, Mounjaro, Rybelsus) but does not cover them for weight management alone. Prior authorization is required. The Texas HHSC maintains a Preferred Drug List, and your provider may need to demonstrate that you've tried other diabetes medications first. For patients with both diabetes and obesity, the diabetes indication is typically sufficient to get approval. There is ongoing legislative discussion about expanding Texas Medicaid to cover anti-obesity medications, but no changes are expected before 2027.

How long does it take to see results on GLP-1 medications in Texas?

Most patients notice reduced appetite within the first 1–2 weeks, though significant weight loss typically takes 8–12 weeks to become clearly visible. In clinical trials, the average weight-loss timeline looks like this: 5% body weight loss by 3 months, 10% by 6 months, and 15–22% by 12–18 months depending on the medication and dose. Individual results vary based on starting weight, dose titration speed, diet and exercise habits, and genetic factors. Texas providers generally recommend giving a GLP-1 at least 12–16 weeks at the full maintenance dose before evaluating whether it's working for you.

---

Related Reading

• FDA Approves New Oral GLP-1 Medication in 2026: What You Need to Know
• GLP-1 Insurance Coverage Expands in 2026: State-by-State Update
• GLP-1 Medications: A New Hope for Addiction and Brain Health?
• Best Protein Powders for GLP-1 Users

---

Sources

1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2021. (STEP 1 trial)
2. Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine, 2022. (SURMOUNT-1 trial)
3. Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." New England Journal of Medicine, 2023. (SELECT trial)
4. Frías JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Obesity." Nature Medicine, 2025. (SURMOUNT-5 trial)
5. Knop FK, et al. "Oral Semaglutide 50 mg Taken Once Daily in Adults with Overweight or Obesity." The Lancet, 2023. (OASIS 1 trial)
6. Pi-Sunyer X, et al. "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management." New England Journal of Medicine, 2015. (SCALE trial)
7. Frías JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." New England Journal of Medicine, 2021. (SURPASS-2 trial)
8. Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity." New England Journal of Medicine, 2023. (Phase 2 results)
9. Rubino DM, et al. "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance." JAMA, 2024. (STEP 4 trial)
10. CDC Behavioral Risk Factor Surveillance System. "Prevalence of Obesity Among Adults, by State." 2024.
11. KFF Employer Health Benefits Survey. "Employer Coverage of GLP-1 Medications." 2024.
12. Texas Department of State Health Services. "Diabetes Prevalence in Texas." 2024.
13. U.S. Census Bureau. "Health Insurance Coverage in the United States." 2024.
14. World Health Organization. "Substandard and Falsified Medical Products." 2023.
15. Novo Nordisk Annual Report. 2025.

---

-- The GLP-1 Daily Team